|
|
|
|
Vol. 19, Issue 3, 822-832, March 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||





*Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan;
Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan;
Institut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique-Unité Mixte de Recherche 6097, 06560 Valbonne, France;
Department of Molecular Cell Biology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan; and ||Signal Transduction Program, The Burnham Institute, La Jolla, CA 92037
Submitted August 10, 2007;
Revised November 28, 2007;
Accepted December 11, 2007
Monitoring Editor: Sandra Schmid
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
-receptor-mediated phagocytosis (Zhang et al., 1998
Like other small GTPases, activities of Arf-family GTPases are primarily controlled by guanine nucleotide exchanging factors (GEFs) and GTPase-activating proteins (GAPs), through regulation of the guanine nucleotide binding states. On the other hand, ubiquitination has recently been shown to be involved in the cellular regulation of several small GTPases. Local levels of RhoA protein are regulated by Smurf-mediated polyubiquitination, which is coupled to proteasome-mediated degradation of RhoA (Wang et al., 2003
). The active form of Rac1 has also been shown to undergo polyubiquitination, and this ubiquitination is also linked to its proteasomal degradation (Lynch et al., 2006
). Ubiquitination of H-Ras also occurs, but primarily as the mono- and di-ubiquitinated forms (Jura et al., 2006
). This ubiquitination does not lead to its immediate proteasomal degradation, but is closely related to the spatial sorting and signal transmission of intracellular H-Ras proteins. E3 components responsible for the ubiquitination of Rac1 and H-Ras have not been identified.
Members of F-box proteins act as subunits of the SCF (Skp1/Cul1/F-box) protein complexes of ubiquitin E3 ligases and primarily determine substrate specificity of ubiquitination through their direct interaction with substrates (Cardazo and Pagano, 2004
). The SCF complexes include the common components of Cullin1 (Cul1) and Skp1, the latter of which directly binds to F-box proteins (Cardazo and Pagano, 2004
). On the other hand, the Sec7 domain is known to generally encode the GEF domain for Arf-family GTPases (Jackson, 2003
). The database of F-box proteins includes Fbx8, which contains an F-box domain and a putative Sec7 domain (Jin et al., 2004
). Fbx8 was originally identified as a Skp1-binding protein by yeast two hybrid screening (Cenciarelli et al., 1999
; Winston et al., 1999
), and this binding has been subsequently confirmed biochemically (Winston et al., 1999
). However, the property to bind to Skp1 is not enough to specify F-box proteins to be components of the E3 ligase (Cardazo and Pagano, 2004
), and functions of Fbx8 remain unknown.
Here we show that Fbx8 is a component of the SCF complex and mediates ubiquitination of Arf6, whereas other Arf isoforms are not notably ubiquitinated by virtue of Fbx8. We found that Fbx8-mediated Arf6 ubiquitination is noncanonical, in other words not linked to its immediate proteasomal degradation, whereas Fbx8 itself is polyubiquitinated and appears to be immediately degraded proteasomally. Fbx8 mRNA is expressed widely in many tissues and cells (Ilyin et al., 2000
), similar to Arf6 mRNA (Lebeda et al., 2003
). However, expression of Fbx8 mRNA has been reported to be lost in some tumor cells, such as colon cancer cells and lung cancer cells, whereas it is expressed in normal colon and lung cells (Ilyin et al., 2000
). We found that Fbx8 protein expression is lost in highly invasive breast cancer cells, including MDA-MB-231, whereas these cells express Fbx8 mRNA. On the other hand, normal mammary epithelial cells express both Fbx8 mRNA and protein. Arf6 is overexpressed in these highly invasive breast cancer cells, and Arf6 activity is essential for their invasive activities (Hashimoto et al., 2004a
). We demonstrate that forced expression of Fbx8 in invasive breast cancer cells suppresses their Arf6 activities and also Matrigel invasion activities. Our results indicate that Fbx8 mediates the noncanonical ubiquitination of Arf6 and hence provides a novel mechanism of the suppressive control of Arf6 activity and function.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Antibodies
The rabbit polyclonal anti-Fbx8 antibody was raised against recombinant GST-Fbx8 protein, containing aa 1-67 of Fbx8 fused in frame to the carboxyl-terminus of glutathione S-transferase (GST), and affinity-purified using this GST-Fbx8 protein. The rabbit polyclonal antibody against human Arf6 was raised against aa 131-144 of human Arf6 and was affinity-purified using this peptide. For injecting into rabbits, this peptide was conjugated with keyhole limpet hemocyanin, via the addition of a cysteine to the amino terminus of the peptide. Antibodies against the following peptides and proteins were purchased from commercial sources: Arf6 (Santa Cruz Biotechnology, Santa Cruz, CA), ubiquitin (Covance, Berkley, CA), hemagglutinin (HA), Myc (clone 9E10) and enhanced green fluorescent protein (EGFP; Babco, Richmond, CA), FLAG and β-actin (Sigma), GST (Upstate Biotechnology, Lake Placid, NY, for immunoblotting, and Abcam, Cambridge, UK, for immunofluorescence), Crk (BD Biosciences, San Jose, CA), EGFR (Abcam, Cambridge, UK), and Arf1 (Abcam). Affinity-purified Cy2- or horseradish-conjugated donkey anti-rabbit IgG antibodies and affinity-purified Cy3- or horseradish-conjugated donkey anti-mouse IgG antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA).
cDNAs
Mouse Arf isoform cDNAs, each fused in frame to the amino-terminus of FLAG-tag, were ligated into HindIII-XbaI sites of pcDNA3. Site-directed mutations were introduced using PCR. PCR-amplified full-length mouse Fbx8 cDNA, its
Sec7 mutant, in which the carboxy-terminal 133-320 aa were deleted, and its
Fbox mutant, in which the amino-terminal 1-113 aa were deleted, were each cloned into BamHI-NotI sites of pEBG (encoding GST) to be fused in frame to the carboxy-terminus of GST. Human Cul1 cDNA, fused in frame to the carboxy-terminus of Myc-tag, was ligated into Asp718I-NotI sites of pcDNA3.1. Human Skp1 cDNA, fused in frame to the carboxy-terminus of FLAG-tag, was ligated into NheI-XhoI sites of pcDNA3.1. pMT123, encoding HA-tagged ubiquitin, was a gift from M. Treier. PCR-amplified cDNA fragments of full-length Fbx8, the Sec7 domain of Fbx8 (aa 114-320), GGA3 (aa 1-226), the Sec7 domain of human ARNO (aa 72-252), and the zinc-finger domain of human AMAP1 (aa 439-562) were each cloned into BamHI-EcoRI sites of pGEX. EFA6 cDNA, encompassing the entire coding region, was subcloned into pET3a vector, as described previously (Chavrier and Franco, 2001
).
cDNA Transfection
For the coprecipitation assay, 2.0 x 105 Cos-7 cells were transfected with 1.0 µg pcDNA3.1/Myc-Cul1 and 1.5 µg pEBG/Fbx8, together with or without 1.0 µg pcDNA3.1/FLAG-Skp1, using Fugene6 (Roche, Indianapolis, IN) according to the manufacturer's instructions. When necessary, empty pEBG vector (0.5 µg) or sonicated calf thymus DNA was used instead of pEBG/Fbx8.
For the ubiquitination assays, 2.0 x 105 Cos-7 cells were transfected with 0.5 µg pcDNA/Arf-FLAG, 0.5 µg pMT123 (encoding HA-ubiquitin), and 1.5 µg of pEBG/Fbx8, pEBG/Fbx8
Fbox, or pEBG/Fbx8
Sec7, using Fugene6 according to the manufacturer's instructions. Cells were incubated for 24 h before analyses unless otherwise indicated. When necessary, empty pEBG vector (0.5 µg) or sonicated calf thymus DNA was used instead of pEBG/Fbx8 or pMT123.
For the Matrigel invasion assays, 5.0 x 105 MDA-MB-231 cells were transfected with 6.0 µg of pEBG/Fbx8, pEBG/Fbx8
Sec7, or pEBG/Fbx8
Fbox; or 2.0 µg of pEBG plus 4.0 µg of pcDNA3 using TransIT-LT1 (Mirus, Madison, WI) according to the manufacturer's instructions. Lipofectamine LTX (Invitrogen) was used for transfection of Hs578T and MDA-MB-435s cells. Two micrograms of pEGFP-C1 were simultaneously transfected to identify transfection-positive cells. To examine the effects of coexpression of GST-Fbx8 with Arf6-FLAG or Arf6 3/7/174R-FLAG, cells were first stably transfected with pcDNA/Arf6-FLAG or pcDNAArf6 3/7/174R-FLAG, together with pBabe puro (Morgenstern and Land, 1990
), and selected for 1 wk using puromycin (1 µg/ml). These cells were then further transiently transfected with pEBG/Fbx8 and pEGFP-C1 before analysis.
Small Interfering RNA
Duplex oligonucleotides for mouse Fbx8 silencing, 5'-AACUGACCUUUGCUUGGCUUCUU-3' and 5'-GAAGCCAAGCAAAGGUCAGUUUU-3', were chemically synthesized and purified by Sigma-PROLIGO (Boulder, CO). The small interfering RNA (siRNA) duplex for Arf6 silencing has been described previously (Hashimoto et al., 2004a
). An siRNA duplex with an irrelevant sequence (siCONTROL, RISC-free siRNA1; Dharmacon, Lafayette, CO) was used as a control. NMuMG cells were transfected with 20 nM oligonucleotide duplexes using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions and incubated for 24 h before analysis, unless otherwise described.
Immunoblotting
Cells were lysed with RIPA buffer, as described previously (Hashimoto et al., 2004a
), supplemented with 200 µM of iodoacetamide and 800 µM of N-ethylmaleimide (Sigma), unless otherwise indicated. For in vitro protein-binding analyses, cells were lysed with 1% NP-40 buffer (Hashimoto et al., 2004a
) supplemented with 200 µM of iodoacetamide and 800 µM of N-ethylmaleimide. For detection of endogenous ubiquitination of Arf6, cells were lysed with 1% SDS, boiled for 10 min, then reconstituted into RIPA buffer, and subjected to immunoprecipitation using a polyclonal anti-Arf6 antibody. GST-fusion proteins were precipitated using glutathione-Sepharose beads. Primary antibodies were precipitated using protein G-Sepharose beads. Subcellular fractionation was performed using a detergent-free hypotonic buffer (Mazaki et al., 2001
), supplemented with 200 µM of iodoacetamide and 800 µM of N-ethylmaleimide. SDS-PAGE, immunoblotting analysis, and protein detection by enzyme-linked chemiluminescence were performed as described previously (Hashimoto et al., 2004a
). Prestained protein molecular size markers (Nacalai tesque, Kyoto, Japan) were used. Each experiment was performed at least three times, and representative figures are shown.
In Vitro GEF Assay
The GEF assay was performed as previously described (Chavrier and Franco, 2001
), in which 1 µM recombinant Arf6 protein was incubated with 300 nM GST-Fbx8, 60 nM GST-Fbx8 Sec7, or 200 nM EFA6 in a reaction buffer (50 mM HEPES-NaOH, pH 7.5, 1 mM MgCl2, 100 mM KCl, 1 mM dithiothreitol, and 1.5 mg/ml azolectin vesicles) in the presence of 10 µM [35S]GTP-
-S (
1250 Ci/mmol; NEN-Perkin Elmer-Cetus, Wellesley, MA); and radioactivities associated with Arf6 were measured by trapping them with nitrocellulose membranes (Schleicher & Schuell, Keene, NH).
Immunofluorescent Microscopy
Cells were fixed in 4% paraformaldehyde in phosphate-buffered saline, as described previously (Mazaki et al., 2001
), and then permeabilized by 0.2% saponin in phosphate-buffered saline and labeled with mouse monoclonal anti-Arf6 antibody, coupled with Cy3-conjugated anti-mouse IgG, and rabbit polyclonal anti-GST antibody, coupled with Cy2-conjugated anti-rabbit IgG. Fluorescence microscopy was performed using a confocal laser-scanning microscope (LSM 510, Carl Zeiss, Thornwood, NY) and the associated software.
Arf Activities
Activities of cellular Arf GTPases were measured by pulling down their GTP-bound forms using GST-GGA (Golgi-localizing,
-adaptin ear homology domain, Arf-binding protein) from each cell lysate (300 µg) and immunoblotting precipitated Arf GTPases with their antibodies, as previously described (Luton et al., 2004
). Each experiment was performed at least three times, and representative figures are shown.
RT-PCR
Extraction of total RNA and subsequent cDNA synthesis were performed as described previously (Hashimoto et al., 2004a
). PCR amplification was performed as follows: 95°C for 9 min followed by 35 cycles of 95°C for 30 s, 60°C for 1 min, and 72°C for 1 min. Primers for Fbx8 cDNA were, 5'-TATGTCCAAGGGTATCCTAGA-3' and 5'-TTATGCAGCCACATGGCCAATAAG-3'. Primers for β-actin cDNA (Takara Shuzo, Kyoto, Japan) were used as a control.
Matrigel Invasion Assay
Matrigel invasion assay was performed using Biocoat Matrigel chambers (BD Bioscience), as described previously (Hashimoto et al., 2004a
). Briefly, 1 x 105 cells were seeded on the upper wells of 24-well chambers in the absence of serum, in which the lower wells were filled with conditioned medium of NIH 3T3 cells cultured for 24 h in the absence of serum. After incubation for 6 h, cells migrated out onto the lower surface of the membrane through Matrigel and were fixed in 4% paraformaldehyde, and EGFP-positive cells (hence positive for the cDNA transfection) were then counted by detecting their autofluorescence, using an LSM 510 laser scanning microscope. Percent cell invasion was calculated by dividing the number of transfection-positive cells transmigrated into the lower wells by the number of transfection-positive cells initially applied onto the upper wells.
| RESULTS |
|---|
|
|
|---|
Sec7) or the F-box domain (
Fbox) did not induce ubiquitination of Arf6-FLAG (Figure 1B). A faint
30-kDa band was also detected as a ubiquitinated product of Arf6-FLAG (Figure 1B, indicated by an asterisk), which likely represents the intermediate, monoubiquitinated form of Arf6-FLAG. On the other hand, Arf1-FLAG and Arf4-FLAG did not undergo such Fbx8-mediated dense ubiquitination, whereas very weak ubiquitination of Arf4-FLAG was observed in the presence of GST-Fbx8 (Figure 1B). We also confirmed that the smear bands of the immunoprecipitated Arf6-FLAG, reactive with an anti-HA antibody, do not represent simple contamination of HA-ubiquitin in these immunoprecipitants: we boiled the anti-FLAG immunoprecipitants in 1% SDS, and then reprecipitated them with an anti-FLAG antibody after be reconstituting into RIPA buffer (Supplementary Figure S1A). Moreover, we found that the Fbx8 Sec7 domain directly interacts with Arf6 in vitro (Supplementary Figure S1B).
|
Ubiquitination generally occurs at lysines (Hershko and Ciechanover, 1992
). Arf1 and Arf6 share high sequence similarity, and there are three lysines, Lys3, 7 and 174, unique to Arf6. Because Fbx8 does not recognize Arf1 as a ubiquitination substrate, we made an Arf6 mutant in which these three lysines were simultaneously changed to arginines (3/7/174R). This mutant of Arf6-FLAG always appeared as a doublet for unknown reasons, which could be detected both the anti-Arf6 and the anti-FLAG antibody immunoblot. This mutant of Arf6-FLAG did not undergo Fbx8-mediated ubiquitination (Figure 1C). These results further support the specificity of Fbx8 toward Arf6 and suggest that these three lysines of Arf6 are candidate sites for Fbx8-mediated ubiquitination (also see below). It is difficult to clearly distinguish whether high-molecular-weight smears bands of ubiquitination represent polyubiquitination of the target protein or its mono-ubiquitination at multiple sites (Haglund et al., 2003
). Given that these three lysines are possible sites of Arf6 ubiquitination and that the smear bands of Arf6 ubiquitination are very high in molecular weight, larger than 70–90 kDa in appearance, it is likely that Arf6 is mostly polyubiquitinated.
Sec7 domains generally exhibit GEF activities for Arf GTPases. We next examined whether Fbx8 acts as a GEF for Arf6. Biochemical measurements showed no appreciable GEF activity of Fbx8, as well as its Sec7 domain alone toward Arf6, under conditions in which EFA6 exhibited robust GEF activity toward Arf6 (Chavrier and Franco, 2001
; Figure 1E).
Cos-7 cells express Arf6 and Fbx8 endogenously (see Figure 1D). We then sought to obtain evidence supporting that endogenous Arf6 is ubiquitinated by endogenous Fbx8. We found that immunoprecipitation of ubiquitinated Arf6 is very difficult by using commercially available anti-Arf6 antibodies (data not shown). Comparison of the primary amino acid sequences among Arf isoforms revealed that amino acids (aa) 131-144 of human Arf6 is most divergent from the other human Arf isoforms. We therefore generated a rabbit polyclonal antibody against a synthetic peptide of this aa 131-144 sequence, which was affinity-purified before use, and confirmed the specificity of this polyclonal antibody against Arf6, but not other Arf isoforms (Supplementary Figure S2). We then found that this polyclonal antibody can precipitate endogenous Arf6, which was once boiled in 1% SDS and reconstituted into RIPA buffer. Using this polyclonal antibody, we immunoprecipitated endogenous Arf6 from Cos-7 cell lysates, which were once boiled and reconstituted into RIPA buffer. Reblotting of these anti-Arf6 immunoprecipitants by a mouse anti-ubiquitin antibody revealed high-molecular-weight smear bands (Figure 1F). Smear bands of Arf6 ubiqutination with high molecular weights (>70–90 kDa in appearance) are most likely to represent polyubiquitination. We also observed ubiquitination bands at about 35–40 kDa, although it is unknown whether they represent monoubiquitination of Arf6 at multiple sites or intermediates of Arf6 polyubiquitination (Figure 1F). All of these bands, reactive with an anti-ubiquitin antibody, almost disappeared when cells were treated with Fbx8 siRNA, whereas they were increased when cells were transfected with GST-Fbx8 (Figure 1F). We also confirmed that such smear bands of anti-Arf6 immunoprecipitants substantially disappeared when cells were treated with Arf6 siRNA (Figure 1F). These results and the results described above collectively indicate that Fbx8 mediates the ubiquitination of Arf6.
Limited Colocalization of Fbx8 with Arf6 at Cell Peripheries
To determine which populations of Arf6 proteins are potential targets for Fbx8, we next examined the subcellular colocalization of Fbx8 with Arf6. For this, we again used Cos-7 cells expressing GST-Fbx8, because endogenous expression of Fbx8 in Cos-7 cells was too low to be detected clearly by immunolabeling. The inactive form of Arf6, as seen in serum-starved cells, is mostly localized to the cytoplasm (Peters et al., 1995
; D'Souza-Schorey et al., 1995
; Radhakrishna et al., 1996
, 1997
; Hashimoto et al., 2004b
). We found that GST-Fbx8 is also predominantly localized to the cytoplasm in serum-starved cells (Figure 2A). However, GST-Fbx8 and Arf6 did not colocalize well with each other in the cytoplasm in these serum-starved cells, although their very minor colocalization in the cytoplasm may occur (Figure 2A). Consistently, Fbx8-mediated ubiquitination of Arf6 did not occur efficiently in these serum-starved cells, compared with that in cells cultured in the presence of serum (Figure 2B). This inefficiency of Arf6 ubiquitination is unlikely to be due to a general inefficiency of protein ubiquitination in these serum-starved cells, because it has been shown that protein ubiquitination can occur in such serum-starved cells (de Melker et al., 2004
). We also confirmed that EGF-induced ubiquitination of EGF receptors occurs efficiently in these serum-starved cells (data not shown).
|
Noncanonical Nature of the Fbx8-mediated Ubiquitination of Arf6
Protein ubiquitination was originally identified as a signal for proteasome-mediated rapid degradation (Hershko and Ciechanover, 1992
). Recently, a number of reports have described noncanonical types of protein ubiquitination, which are not immediately coupled to proteasome-mediated degradation (Sun and Chen, 2004
). We then investigated the nature of Fbx8-mediated Arf6 ubiquitination, by using proteasome inhibitors. Because ubiquitination of endogenous Arf6 by endogenous Fbx8 can only be detected very faintly, we again used a reconstitution system using Cos-7 cells. Cos-7 cells expressing Arf6-FLAG, GST-Fbx8, and HA-ubiquitin were treated with MG132, Epoxomycin, Lactacystin, and an inactive derivative of MG132, ZLLH. We also used a calpain inhibitor, E64, as another control. None of these compounds notably increased the amounts of ubiquitinated Arf6-FLAG (Figure 3A). Amounts of the nonubiquitinated form of Arf6-FLAG were also not notably changed by these compounds (Figure 3A). We also examined the effects of these inhibitors in cDNA-untransfected Cos-7 cells and found that the amounts of endogenous Arf6 in untransfected Cos-7 cells are also not notably changed by these treatments (Figure 3B). These results suggest that Fbx8-mediated ubiquitination of Arf6 may not be immediately linked to proteasomal degradation of Arf6.
|
Fbx8 Acts to Suppress Arf6 Activity
Given that Fbx8-induced Arf6 ubiquitination is noncanonical and not immediately linked to proteasomal degradation of Arf6, we then investigated the possible roles of this ubiquitination. For this, we examined the effects of Fbx8 knockdown on the activity of Arf6. Cos-7 cells express a low level of Arf6 protein (Supplementary Figure S3), and we found that it is difficult to detect clearly the possible changes of Arf6 activity in Cos-7 cells by biochemical methods, such as the GGA pulldown method (data not shown). On the other hand, NMuMG cells, a mouse normal mammary epithelial cell line, expressed a several fold higher amount of Arf6 protein endogenously than that in Cos-7 cells (Supplementary Figure S3). NMuMG cells also express Fbx8 protein (see Figure 4). We found that activities of endogenous Arf6 in NMuMG cells are significantly increased upon Fbx8 siRNA-treatment (Figure 4). Activity of endogenous Arf1, used as a control, was not notably changed by Fbx8 siRNA (Figure 4). Therefore, Fbx8 appears to suppress the activities of Arf6. However, it should be noted that protein levels of the endogenous, nonubiquitinated form of Arf6 are not notably increased (nor decreased) by Fbx8 siRNA-treatment (Figure 4). This is consistent with the above notion that only a small fraction of Arf6 may be targeted by Fbx8. In a separate experiment, we confirmed that endogenous Arf6 ubiquitination also occurs in NMuMG cells, a ubiquitination that disappears when endogenous Fbx8 is knocked down by Fbx8 siRNA-treatment, as in the case of Cos-7 cells (Figure 4). Similar to Cos-7 cells, the protein level of endogenous Fbx8, but not Arf6, was also increased in NMuMG cells when these cells were treated with proteasomal inhibitors (data not shown).
|
|
|
Sec7 and
Fbox mutants of Fbx8 do not suppress their Arf6 activity and Matrigel invasion activity (Figure 6, C and D) and that Arf6 ubiquitination is evoked when cells are transfected with GST-Fbx8 (Figure 6E). We furthermore confirmed that coexpression of the 3/7/174R mutant of Arf6, together with GST-Fbx8, can restore the invasion activity of MDA-MB-231 cells, whereas wild-type Arf6 cannot (Figure 6D). Expression of each protein in these experiments, including EGFP used as a marker for the transfection, was assessed by immnoblotting (Supplementary Figure S4). These results indicate that Fbx8 has the potential to suppress Arf6 activity that is involved in invasion, most likely via its activity to ubiquitinate Arf6, and suggest that impairment of Fbx8 protein expression may contribute to the acquisition of invasive phenotypes of some breast cancer cells. | DISCUSSION |
|---|
|
|
|---|
Our results and results in the literature reveal that Fbx8 expression is impaired in some tumor cells. In the case of colon and lung cancer cells, mRNA expression of Fbx8 has been shown to be lost, as mentioned earlier. In the case of the invasive breast cancer cells that we examined, protein expression of Fbx8 is impaired, although these cells express Fbx8 mRNA. Therefore, the genetic alterations and mechanisms involved in the loss of Fbx8 expression appear to vary among different types of tumor cells. We demonstrated that forced expression of Fbx8 suppresses Arf6 activities and the invasive activities of these breast cancer cells. Therefore, loss of Fbx8 expression appears to contribute to the development of malignancy of some breast cancer cells. It will hence be interesting to analyze the expression of Fbx8, in its protein and mRNA, in clinical specimens of various human tumors.
Fbx8 appears to ubiquitinate only small, limited amounts of cellular Arf6 and is yet able to significantly suppress its activity. Our results show that only a limited fraction of cellular Arf6 colocalizes with Fbx8. Our results also show that knockdown of Fbx8 by siRNA does not notably increase the amounts of the nonubiquitinated form of Arf6, whereas activity of intracellular Arf6 is significantly increased in the Fbx8 siRNA-treated cells. Consistently, the amounts of nonubiquitinated Arf6 is not notably decreased even when Fbx8 is overexpressed and dense ubiquitination of Arf6 occurs, whereas Arf6 activity is substantially blocked under these conditions (see Figures 1B and 6C). Our analyses moreover show that Arf6 and Fbx8 become well colocalized with each other only after they are both recruited to the plasma membrane, whereas not all Arf6 proteins recruited to the plasma membrane are colocalized with Fbx8. The active form of Arf6 is predominantly localized to the plasma membrane, whereas the inactive form of Arf6 is predominantly localized to the cytoplasm, as mentioned earlier. On the other hand, Arf6 proteins recruited to the plasma membrane may not necessarily be in the active form. Therefore, it is conceivable that Fbx8 is able to target Arf6, when Fbx8 and Arf6 are both recruited to the plasma membrane and that such populations of Arf6, which are potential targets of Fbx8, may be in the active form or under processes to be activated. On the other hand, it is suggested that Arf6 can also be activated and function at cytoplasmic endomembranes (Brown et al., 2001
). We have not yet analyzed in detail whether Fbx8 targets such a population of Arf6, which is activated and functions in the cytoplasm.
The important question that remains is, what are the biological contexts in which Fbx8-mediated suppressive control of Arf6 activity occurs. In general, substrate proteins are covalently modified, such as by phosphorylation and hydroxylation, to be recognized by their cognate E3 ligases (Glickman and Ciechanover 2002
; Kaelin, 2005
). It is also well known that several E3 ligases ubiquitinate immature or misfolded proteins for their degradation (Meusser et al., 2005
). We showed that myristoylation of Arf6 is necessary for its ubiquitination by Fbx8, and it is unlikely that Fbx8 ubiquitinates premature or misfolded Arf6 molecules. On the other hand, Smurf1 recognizes the nucleotide-binding status of RhoA to ubiquitinate this small GTPase (Wang et al., 2003
). We found, however, that both the GTP-bound form [Arf6 (Q67L)] and the GDP-bound form [Arf6 (T27N)] of Arf6 can be ubiquitinated almost equally when they are coexpressed with GST-Fbx8 in Cos-7 cells (Supplementary Figure S5). Recently, isomerization of proline residues of cyclinE molecules was suggested to provide a cue to be recognized by the E3 ligase SCFhcd4
(van Drogon et al., 2006
), whereas it is also known that cyclinE, which is freed from CDK2 and is not phosphorylated, is targeted by SCFSkp2 for ubiquitination (Nakayama et al., 2000
). On the other hand, it has been reported that recognition of Smad1 by Smurf1 may be independent of the modification of Smad1 and simply mediated by their interaction through the WW domain of Smurf1 and the PPXY motif of Smad1 (Zhu et al., 1999
). Ubiquitination of Aux/IAA, a transcription repressor, by virtue of an F-box protein, TIR, also appears to be independent of the modification of Aux/IAA (Dharmasiri et al., 2005
). A cell-free system of protein ubiquitination in vitro is a powerful way to analyze the precise mechanism of ubiquitination. However, Arf6 is a membrane protein, and we showed that Fbx8-mediated Arf6 ubiquitination occurs in the membrane fraction. At this moment, it is well known that reconstitution in vitro of such protein ubiquitination that takes place at membranes is very difficult. Moreover, our results strongly suggest that Fbx8-mdiated Arf6 ubiquitination is noncanonical. Noncanonical ubiquitinations may utilize ubiquitin lysines other than Lys48 for their polymer formation. However, clear experimental demonstrations of such noncanonical utilization of ubiquitin lysines onto membrane proteins have so far been successful only for a limited number of cases (Geetha et al., 2005
; Jura et al., 2006
). In our case, we also tried in vain to determine which lysines of ubiquitin are utilized for Arf6 modification. The precise mechanisms by which Fbx8 recognizes Arf6 as its substrate for ubiquitination remain totally unknown and await to be determined.
We show that overexpression of Fbx8 increases the levels of Arf6 ubiquitination in Cos-7 cells. Therefore, cellular levels of Fbx8 protein may be one of the factors regulating Arf6 ubiquitination. On the other hand, our results indicate that Fbx8 is ubiquitinated and degraded proteasomally. Therefore, it will be important to clarify mechanism by which Fbx8 is ubiquitinated, together with the mechanism of regulation of this ubiquitination. Whether transcription of Fbx8 gene and levels of Fbx8 mRNA are regulatable and whether the expression of Fbx8 protein is regulated by mechanisms other than its ubiquitination and degradation, such as by translational control of Fbx8 mRNA, should also be investigated. Possible dysfunction of such mechanisms in human tumors also await to be analyzed.
In conclusion, we show that Arf6 has a novel mechanism for its suppressive control through Fbx8. Our results also imply that loss of Fbx8 expression may contribute to tumor malignancy. In the case of RhoA, its ubiquitination by Smurf1 has been implicated such as in cell polarity, motility, and epithelial-mesenchymal transdifferentiation (Wang et al., 2003
) and also in the mesenchymal-type invasion of colon cancer cells (Sahai et al., 2007
). Noncanonical ubiquitination of H-Ras has been shown to be involved in the endosomal association of modified H-Ras and hence in the regulation of Raf/MAP kinase signaling (Jura et al., 2006
). Further understanding of the precise biological contexts and timings in which ubiquitination-mediated regulation of these small GTPases, including Arf6, occur besides their classical regulation by GEFs and GAPs. Also, precise mechanisms as to how these small GTPases become recognized by their cognate E3 ligases will unveil important biological processes in which these small GTPases are crucially involved, such as in cell growth and migration, tissue remodeling, and tumor progression. It may also be worth analyzing whether other Arf isoforms are ubiquitinated by some E3 ligases.
| ACKNOWLEDGMENTS |
|---|
| Footnotes |
|---|
Address correspondence to: Hisataka Sabe (sabe{at}obi.or.jp)
Abbreviations used: Arf6, ADP ribosylation factor 6; GEF, guanine nucleotide exchange factor; GAP, GTPase-activating protein; SCF complex, Skp1/Cul1/F-box complex; GGA, Golgi-localizing,
-adaptin ear homology domain, Arf-binding protein; ARNO, ADP ribosylation factor nucleotide binding site opener; AMAP1, a multidomain Arf GAP protein.
| REFERENCES |
|---|
|
|
|---|
Cardazo, T., and Pagano, M. (2004). The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol 5, 739–751.[CrossRef][Medline]
Cenciarelli, C., Chiaur, D. S., Guardavaccaro, D., Parks, W., Vidal, M., and Pagano, M. (1999). Identification of a family of human F-box proteins. Curr. Biol 9, 1177–1179.[CrossRef][Medline]
Chavrier, P., and Franco, M. (2001). Expression, purification, and biochemical properties of EFA6, a Sec7 domain-containing guanine exchange factor for ADP-ribosylation factor6 (Arf6). Methods Enzymol 329, 272–279.[CrossRef][Medline]
de Melker, A., van der Horst, G., and Borst, J. (2004). Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into Clathrin-coated pits by two distinct modes of Eps15 recruitment. J. Biol. Chem 279, 55465–55473.
Dharmasiri, N., Dharmasiri, S., and Estelle, M. (2005). The F-box protein TIR is an auxin receptor. Nature 435, 441–445.[CrossRef][Medline]
Donaldson, J. G. (2003). Multiple roles for Arf6, Sorting, structuring, and signaling at the plasma membrane. J. Biol. Chem 278, 41573–41576.
D'Souza-Schorey, C., and Stahl, P. D. (1995). Myristoylation is required for the intracellular localization and endocytic function of ARF6. Exp. Cell Res 221, 153–159.[CrossRef][Medline]
D'Souza-Schorey, C., Li, G., Colombo, M. L., and Stahl, P. D. (1995). A regulatory role for ARF6 in receptor-mediated endocytosis. Science 267, 1175–1178.
D'Souza-Schorey, C., Boshans, R. L., McDonough, M., Stahl, P. D., and Aelst, L. V. (1997). A role for POR1, a Rac1-interacting protein, in ARF6-mediated cytoskeletal rearrangements. EMBO J 16, 5445–5454.[CrossRef][Medline]
D'Souza-Schorey, C. (2005). Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol 15, 19–26.[CrossRef][Medline]
D'Souza-Schorey, C., and Chavrier, P. (2006). ARF proteins: roles in membrane traffic and beyond. Nat. Rev. Mol. Cell Biol 7, 347–358.[CrossRef][Medline]
Frank, S., Upender, S., Hanse, S. H., and Casanova, J. E. (1998). ARNO is a guanine nucleotide exchange factor for ADP-ribosylation Factor 6. J. Biol. Chem 273, 23–27.
Geetha, T., Jiang, J., and Wooten, M. W. (2005). Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol. Cell 20, 301–312.[CrossRef][Medline]
Glickman, M. H., and Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev 82, 373–428.
Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P. P., and Dikic, I. (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol 5, 461–466.[CrossRef][Medline]
Hart, M. J., Eva, A., Zangrilli, D., Aaronson, S. A., Evans, T., Cerione, R. A., and Zhenf, Y. (1994). Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product. J. Biol. Chem 269, 62–65.
Hashimoto, S., Onodera, Y., Hashimoto, A., Tanaka, M., Hamaguchi, M., Yamada, A., and Sabe, H. (2004a). Requirement for Arf6 in breast cancer invasive activities. Proc. Natl. Acad. Sci. USA 101, 6647–6652.
Hashimoto, S., Hashimoto, A., Yamada, A., Kojima, C., Yamamoto, H., Tsutsumi, T., Higashi, M., Mizoguchi, A., Yagi, R., and Sabe, H. (2004b). A novel mode of action of an ArfGAP, AMAP2/PAG3/Pap
, in Arf6 function. J. Biol. Chem 279, 37677–37684.
Hershko, A., and Ciechanover, A. (1992). The ubiquitin system for protein degradation. Annu. Rev. Biochem 61, 761–807.[CrossRef][Medline]
Hussain, N. K. et al. (2001). Endocytic protein intersectin-1 regulates actin assembly via Cdc42 and N-WASP. Nat. Cell Biol 3, 927–932.[CrossRef][Medline]
Ilyin, G. P., Rialland, M., Pigeon, C., and Guguen-Guillouzo, C. (2000). cDNA cloning and expression of new members of the mammalian F-box protein family. Genomics 67, 40–47.[CrossRef][Medline]
Jackson, C. L. (2003). The Sec7 family of Arf guanine nucleotide exchange factors. In: Arf family GTPases, R. A. Kahn, Dordrecht, the Netherlands: Kluwer Academic Publications, 71–99.
Jin, J., Cardazo, T., Lovering, R. C., Eliedge, S. J., Pagano, M., and Harper, J. W. (2004). Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18, 2573–2580.
Jura, N., Scotto-Lavino, E., Sobczyk, A., and Bar-Sagi, D. (2006). Differential modification of Ras proteins by ubiquitination. Mol. Cell 21, 679–687.[CrossRef][Medline]
Kaelin, W. G., Jr. (2005). Proline hydroxylation and gene expression. Annu. Rev. Biochem 74, 115–128.[CrossRef][Medline]
Lebeda, R. A., Johnson, S. K., Stewart, M. I., and Haun, R. S. (2003). Sequence, genomic organization, and expression of human ADP-ribosylation factor 6 (ARF6): a class III ARF. DNA Cell Biol 22, 737–741.[CrossRef][Medline]
Logsdon, J. M., and Kahn, R. A. (2003). The Arf family tree. In: Arf family GTPases, R. A. Kahn, Dordrecht, the Netherlands: Kluwer Academic Publications, 1–21.
Luton, F., Klein, S., Chauvin, J. P., Le Bivic, A., Bourgoin, S., Franco, M., and Chardin, P. (2004). EFA6, exchange factor for ARF6, regulates the actin cytoskeleton and associated tight junction in response to E-cadherin engagement. Mol. Biol. Cell 15, 1134–1145.
Lynch, E. A., Stall, J., Schmidt, G., Chavrier, P., and D'Souza-Schorey, C. (2006). Proteasome-mediated degradation of Rac1-GTP during epithelial cell scattering. Mol. Biol. Cell 17, 2236–2242.
Mazaki, Y. et al. (2001). An ADP-ribosylation factor GTPase-activating protein Git2-short/KIAA0148 is involved in subcellular localization of paxillin and actin cytoskeletal organization. Mol. Biol. Cell 12, 645–662.
Meusser, B., Hirsch, C., Jarosch, E., and Sommer, T. (2005). ERAD: the long road to destruction. Nat. Cell Biol 7, 766–772.[CrossRef][Medline]
Morgenstern, J. P., and Land, H. (1990). Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18, 3587–3596.
Nakayama, K. et al. (2000). Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J 19, 2069–2081.[CrossRef][Medline]
Onodera, Y. et al. (2005). Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J 24, 963–973.[CrossRef][Medline]
Palacios, F., Schweitzer, J. K., Boshans, R. L., and D'Souza-Schorey, C. (2002). ARF6-GTP recruits Nm23–H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly. Nat. Cell Biol 4, 929–936.[CrossRef][Medline]
Pasqualato, S., Menetrey, J., Franco, M., and Cherfils, J. (2001). The structural GDP/GTP cycle of human Arf6. EMBO Rep 2, 234–238.[CrossRef][Medline]
Peters, P. J., Hsu, V. W., Ooi, C. E., Finazzi, D., Teal, S. B., Oorschot, V., Donaldson, J. G., and Klausner, R. D. (1995). Overexpression of wild-type and mutant ARF1 and ARF 6, distinct perturbations of nonoverlapping membrane compartments. J. Cell Biol 128, 1003–1017.
Radhakrishna, H., Klausner, R. D., and Donaldson, J. G. (1996). Aluminum fluoride stimulates surface protrusions in cells overexpressing the ARF6 GTPase. J. Cell Biol 134, 935–947.
Radhakrishna, H., and Donaldson, J. G. (1997). ADP-ribosylation factor 6 regulates a novel plasma membrane recycling pathway. J. Cell Biol 139, 49–61.
Radhakrishna, H., Al-Awar, O., Khachikian, Z., and Donaldson, J. G. (1999). ARF6 requirement for Rac ruffling suggests a role for membrane trafficking in cortical actin rearrangements. J. Cell Sci 112, 855–866.[Abstract]
Sabe, H. (2003). Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. J. Biochem 134, 485–489.
Sahai, E., Garcia-Medina, R., Pouyssegur, J., and Vial, E. (2007). Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility. J. Cell Biol 176, 35–42.
Sun, L., and Chen, Z. L. (2004). The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol 16, 119–126.[CrossRef][Medline]
Tague, S. E., Muralidharan, V., and D'Souza-Schorey, C. (2004). ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc. Natl. Acad. Sci. USA 101, 9671–9676.
van Drogon, F., Sangfelt, O., Malyukova, A., Matskova, L., Yeh, E., Means, A. R., and Reed, S. I. (2006). Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23, 37–48.[CrossRef][Medline]
Volpicelli-Daley, L. A., Li, Y., Zhang, C. J., and Kahn, R. A. (2005). Isoform-selective effects of the depletion of ADP-ribosylation factors 1–5 on membrane traffic. Mol. Biol. Cell 16, 4495–4508.
Wang, H., Zhang, Y., Ozdamar, B., Ogunjimi, A. A., Alexandrova, E., Thomsen, G. H., and Wrana, J. L. (2003). Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 302, 1775–1779.
Winston, J. T., Koepp, D. M., Zhu, C., Elledge, S. J., and Harper, J. W. (1999). A family of mammalian F-box proteins. Curr. Biol 9, 1180–1182.[CrossRef][Medline]
Zhang, Q., Cox, D., Tseng, C. C., Donaldson, J. G., and Greenberg, S. (1998). A requirement for Arf6 in Fc
receptor-mediated phagocytosis in macrophages. J. Biol. Chem 273, 19977–19981.
Zhu, H., Kavsak, Abdollah, P. S., Wrana, J. L., and Thomsen, G. H. (1999). A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400, 687–693.[CrossRef][Medline]
| |||||||||||||